Progynys Solid Earnings Have Been Accounted For Conservatively
| PGNY Stock | USD 15.41 0.33 2.10% |
Slightly above 61% of Progyny's investor base is looking to short. The analysis of overall sentiment of trading Progyny stock suggests that many investors are alarmed at this time. Progyny's investing sentiment can be driven by a variety of factors including economic data, Progyny's earnings reports, geopolitical events, and overall market trends.
Progyny |
The market seemed underwhelmed by the solid earnings posted by Progyny, Inc. recently. Our analysis...
Read at simplywall.st
 |
Progyny Fundamental Analysis
We analyze Progyny's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Progyny using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Progyny based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Progyny is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Progyny Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Progyny stock to make a market-neutral strategy. Peer analysis of Progyny could also be used in its relative valuation, which is a method of valuing Progyny by comparing valuation metrics with similar companies.
Peers
Progyny Related Equities
| EVH | Evolent Health | 4.55 | ||||
| PHR | Phreesia | 2.65 | ||||
| DH | Definitive Healthcare | 1.49 | ||||
| VEEV | Veeva Systems | 0.08 | ||||
| HCAT | Health Catalyst | 0.12 | ||||
| TDOC | Teladoc | 0.19 | ||||
| TXG | 10X Genomics | 0.43 | ||||
| HSTM | HealthStream | 0.52 | ||||
| GDRX | Goodrx Holdings | 1.22 | ||||
| NRC | National Research | 1.40 | ||||
| CERT | Certara | 1.98 | ||||
| PRVA | Privia Health | 2.27 | ||||
| SLP | Simulations Plus | 2.61 |
Additional Tools for Progyny Stock Analysis
When running Progyny's price analysis, check to measure Progyny's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Progyny is operating at the current time. Most of Progyny's value examination focuses on studying past and present price action to predict the probability of Progyny's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Progyny's price. Additionally, you may evaluate how the addition of Progyny to your portfolios can decrease your overall portfolio volatility.